Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer

HER2-positive breast cancer correlates with more aggressive tumor growth, a poorer prognosis and reduced overall survival. Currently, trastuzumab (Herceptin), which is an anti-HER2 antibody, is one of the key drugs. There is evidence indicating that conjugation of trastuzumab with chemotherapy drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Yiwen, Xu, Zhiyuan, Chen, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058718/
https://www.ncbi.nlm.nih.gov/pubmed/29405790
http://dx.doi.org/10.1080/10717544.2018.1435746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058718/
https://www.ncbi.nlm.nih.gov/pubmed/29405790
http://dx.doi.org/10.1080/10717544.2018.1435746

Ejemplares similares